By Brazil Stock Guide – The race for Ozempic (semaglutide) generics, from Novo Nordisk (NYSE: NVO), is accelerating in Brazil. Local players such as EMS, Hypera (B3: HYPE3) and Biomm (B3: BIOM3) are moving ahead of patent expirations to compete in a multibillion-real market for diabetes and obesity drugs. Brazil’s health regulator Anvisa said it will prioritize generic approvals, paving the way for cheaper alternatives as early as 2026.
Brazil already has nine synthetic semaglutide applications and three biologics under review. The agency can process three of each category per semester, a pace that falls short of surging demand. The case of liraglutide, an earlier GLP-1 drug, shows the likely impact: in the US, generics debuted with a 30% discount to the wholesale acquisition cost, while in Brazil EMS launched Olire and Lirux about 15% cheaper than branded rivals.
“The market is waiting for GLP-1 generics as a key driver to expand access and lower costs in healthcare,” said a retail-sector report from XP Inc. (B3: XPBR31).
What’s at stake
The arrival of generics could reshape the diabetes and obesity treatment market in Brazil, boosting retail pharmacy margins and opening a fresh revenue stream for local drugmakers. Semaglutide alone generates billions of reais annually and has become a global blockbuster thanks to Ozempic and Wegovy. Still, high manufacturing costs and limited injector pen supply are expected to cap initial discounts at 15% to 20%.
Pharmacies stand to gain the most, as generics typically offer gross margins about twice as high as branded drugs. Novo Nordisk and Eli Lilly (NYSE: LLY), maker of Mounjaro (tirzepatide), will face mounting competition. Tirzepatide remains patent-protected in Brazil until 2035, though Lilly is advancing an oral version, Orforglipron, now slated for FDA submission this year.
In the near term, Brazilian consumers are likely to be the biggest winners, gaining access to therapies once priced out of reach. For domestic pharma companies, the GLP-1 generic wave represents a rare chance to tap one of the industry’s most profitable categories worldwide.
Leave a Reply